Vaccines
Policymakers have a rare chance to salvage the COVID-19 vaccine supply chain developed by CureVac, a heavily subsidized German biotech firm, after its vaccine candidate showed surprisingly poor results in final-stage clinical trials. Despite the setback, CureVac's network can still manufacture 1 billion doses of another effective COVID-19
Vaccines
In an effort to contain the coronavirus disease 2019 (COVID-19) pandemic, the United Kingdom initiated its vaccination campaign on December 8, 2020. To date, more than 77% of the adult population in the U.K. have received at least one dose of the COVID-19 vaccine. A new study published on
Vaccines
A recent exposé has revealed that the Scottish Government's vaccine deployment plan was removed from its website due to concerns over a potential breach of commercial confidentiality agreements with vaccine manufacturers. The plan, released on January 13, included sensitive information about vaccine supplies, which was not supposed to
COVID-19
Moderna Inc. jumped to a fresh record after S&P Dow Jones Indices said it plans to add the company to its benchmark S&P 500 Index next week, replacing Alexion Pharmaceuticals Inc. Meanwhile, its market valuation has surpassed $100 billion, making it one of the largest biotech
Pharmaceutical industry
Moderna Inc. jumped to a fresh record after S&P Dow Jones Indices said it plans to add the company to its benchmark S&P 500 Index next week, replacing Alexion Pharmaceuticals Inc. Meanwhile, its market valuation has surpassed $100 billion, making it one of the largest biotech
COVID-19
The Bureau of Customs-NAIA (BOC-NAIA) cleared 250,800 doses of the Moderna COVID-19 vaccine, developed by American drug firm Moderna, Inc., bringing the total number of Moderna doses to 250,800 since its first arrival on June 27, 2021. This batch of vaccines, the seventh to receive emergency use approval
Pharmaceutical industry
The global market for Generic Drugs is projected to reach a revised size of $507.8 Billion by 2026, growing at a compound annual growth rate (CAGR) of 5.6% over the analysis period. The COVID-19 pandemic has accelerated the growth of the generic drugs market, driven by the need
Vaccines
Researchers in Germany have found evidence that a booster shot of a messenger RNA (mRNA)-based COVID-19 vaccine following prime immunization with AstraZeneca's adenoviral vector-based vaccine is sufficient to achieve high levels of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The heterologous prime-boost regimen using
Vaccines
The regional government of Madeira, an autonomous region in Portugal, has decided to permit entry to visitors with any COVID-19 vaccine, regardless of whether it is approved by Europe's drug regulator or not. This move comes amidst criticism over the EU's digital COVID certificate, which currently
Vaccines
The World Health Organization is urging countries to accept Chinese COVID-19 vaccines as valid for international travel, a move that could challenge western countries to broaden their acceptance of the vaccines. The WHO has authorized emergency use of vaccines produced by Sinovac and Sinopharm, but most European and North American
Pharmaceutical industry
The global market for Mobile Medical Apps is experiencing a significant transformation in the post-COVID-19 era, driven by the increasing adoption of mobile healthcare applications. These apps have revolutionized the healthcare system by providing efficient, cost-effective, and accessible health services. The market is expected to grow at a CAGR of
Pharmaceutical industry
The precision medicine market is projected to cross $112 billion by 2027, driven by technological advancements, increasing use of online collaborative forums, and growing awareness of personalized medication. The diagnostics segment is expected to witness a 13% growth rate through 2027, with biomarker testing being a crucial part of personalized
